Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Great news 4,000,000 share inside buy
Drifts higher after hours Yummies 1.98
Pullbacks of 10% for the time being are quarantined because of the massive interest in ATHX saving lives . Dont make more mistakes
Shadow admits failure and redeemable actions by turning long :) there is hope hahah
Todays Action Dopester Proves me better than you. You failed . I am correct! You lose. I win .
You have been consistently wrong . I hope you have everlasting diaper rash you big baby hahahahaha
Remember Dopester promised everyone that he would tell you when IT WAS time to buy ATHX . He has zero credibility. He lied to you to induce fear and get you to sell ! He is a shrill
Athersys Names Maia Hansen Senior Vice President, Operations and Supply Chain
Why would an emerging pharmaceutical company name a supply chain President if the were not planning to supply a product ? Hmmmmmm ...
I am about to pee myself
1.75 and crickets from the Dopester :)
Dopesters walls and predictions are wrong. He has been consistently wrong. No wall at 1.40 hahahahah
Dopester is hiding in his Coronavirius Bunker waiting on a n95 mask from amazon
Novavax logoNovavax (NASDAQ:NVAX) was upgraded by Zacks Investment Research from a “hold” rating to a “buy” rating in a research report issued to clients and investors on Wednesday, Zacks.com reports. The firm presently has a $7.75 price objective on the biopharmaceutical company’s stock. Zacks Investment Research‘s price objective suggests a potential downside of 18.42% from the stock’s previous close.
According to Zacks, “NOVAVAX INC is a specialty biopharmaceutical company engaged in the research, development and commercialization of proprietary products focused on women’s health and infectious diseases. Their technology platforms involve the use of proprietary, microscopic, organized, non-phospholipid structures as vehicles for the delivery of a wide variety of drugs and other therapeutic products, including certain hormones, anti-bacterial and anti-viral products and vaccine adjuvants. “
Get Novavax alerts:
Several other brokerages also recently commented on NVAX. B. Riley increased their price target on Novavax from $12.00 to $16.00 and gave the company a “buy” rating in a report on Friday, February 28th. HC Wainwright reiterated a “buy” rating on shares of Novavax in a report on Thursday, February 27th. BidaskClub upgraded Novavax from a “hold” rating to a “buy” rating in a report on Tuesday, March 3rd. Cantor Fitzgerald upgraded Novavax from a “neutral” rating to an “overweight” rating and increased their price target for the company from $6.00 to $16.00 in a report on Tuesday. Finally, ValuEngine upgraded Novavax from a “sell” rating to a “hold” rating in a report on Saturday. Two equities research analysts have rated the stock with a hold rating and eight have assigned a buy rating to the stock. The stock currently has an average rating of “Buy” and a consensus price target of $14.91.
1.75 pre market oh my Lord sweet Jesus ))))))
Situation in US: There are at least 8,525 cases of novel coronavirus across all 50 states and 145 people have died. President Trump says he sees the country on a wartime footing and himself as a "wartime president", and that he will be invoking the Defense Production Act. .........VERY BULLISH ON MULTISTEM ....
How does Dopester like dem apples
She will work closely with Mr. Greg Liposky, Senior Vice President and Head of Manufacturing, and the rest of the executive team to establish a premier product supply organization and capabilities oriented to sustainable, large scale commercialization.”
LARGE SCALE COMMERCIALIZATIOn
How does Dopester like dem apples
Dopester tells you that having a supply chain officer means that the multistem product will never come to
Fruition and you should sell your shares because it is going lower. Once again he’s trying to scare you with force truths so you lose money
Dopester thinks commercialization of multi stem is a bad thing
Athersys Names Maia Hansen Senior Vice President, Operations and Supply Chain
Source: Business Wire
Athersys Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Athersys, Inc. (“Athersys” or the “Company”) (NASDAQ: ATHX) announced today the addition of Ms. Maia Hansen, an experienced leader in operations and supply chain management, to the Athersys leadership team. Ms. Hansen has been appointed Senior Vice President, Operations and Supply Chain to help establish and manage a sustainable supply chain built to enable reliable, cost-effective and best in class commercial manufacturing and product distribution capabilities to support commercial success. Ms. Hansen will have overall responsibility for supply chain strategy, related operations and capability building. She will work closely with Mr. Greg Liposky, Senior Vice President and Head of Manufacturing, and the rest of the executive team to establish a premier product supply organization and capabilities oriented to sustainable, large scale commercialization.
Ms. Hansen has extensive operations and supply chain experience in the pharmaceutical, medical device and consumer health sectors. Prior to joining Athersys, Ms. Hansen was a Senior Partner at McKinsey & Company, a global management consulting firm. She worked with clients around the world to develop and optimize end-to-end operations and global supply chains. Her work included the development of operations and supply chain strategy, capability building, manufacturing optimization, go-to-market effectiveness, and digital and analytics. In addition, she has worked with clients to connect operations with corporate strategy and product development. These projects included the development and execution of a manufacturing production system across a large, global network for a leading pharmaceutical company. Her work also enabled a health care company to improve
Dopester lies to you all when stock was low to shake you out of position. He sells snake oil. He worse than a used car salesmen. Even strippers have more credibility and fun too hahaha
Dopester thinks when market maker paints the tape at end of day it means something hahahahahhahah he stupid
Dopester thinks when “Master Moe” paints the tape at end of day it means something hahahahahhahah he stupid
Dopester fails again 1.70 after hours hahaha he is always wrong
For a vicious day in the market ATHX HELD UP LIKE A CHAMPION
The KungFlu going to raise awareness of ARDS .
Volume is considerably higher in the last couple of days, which is what you like to see during a move up.
HDopester will be dumpster diving for his next meal because of his short losses
HDopester needs a ventilator for ARDS CASE HE CAUGHT THIS WEEK
When they announce the BARDA funding specifics, this will explode.
The Defense Production Act (DPA) was enacted during the Cold War to allow the president to cajole — and even coerce industry . Trump enacted this act today. This is setting up for a wonderful play
Fourth Quarter and Full Year 2019 Earnings - Company announces #ARDS program has been designated by BARDA as a "Highly Relevant" program for #COVID19 and other pathogens. $ATHX
Lots of oney to be spent ..... barda funding will not take long ...........Glad we had that initial collaboration with catapult in the UK to fund the initial ARDS trial ....or we would not be in this position right now
anyone listening to Cuomo speak? Is he expecting the need for 54K ventilators in New York? ?? Rate of hospitalization is 23%!
Failure here. Looks to go to the pennies
HDopester needs a ventilator for ARDS CASE HE CAUGHT THIS WEEK
Other than placing patients on a ventilator, there is no effective treatment for ARDS. In January, in the early stages of the COVID-19 outbreak, as part of the U.S. Government's COVID-19 CoronaWatch program, we were approached by BARDA in its leadership role focused on expediting diagnostics, vaccines, antivirals and therapeutic treatments for these patients. After undergoing multiple reviews, we are pleased to announce that MultiStem® was designated as a “Highly Relevant” therapeutic for COVID-19 by BARDA. We now are working to expedite the further advancement
The shift at ATHERSYS is amazing. My interest in this co has been focused on Stroke for 5 years now. Within a matter of weeks because of the CV we have done a 180 and are now focusing on ARDS. Fact is we have potential treatments for "TWO" of the greatest threats to the health of the world! This isn't even counting Trauma ! WOW
Dopester has lost his grip and will soon fade away and assume a new alias hahahah claiming he was long